Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
View Patent ↗Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.
1. A method to treat a leukemia in a human patient, said method comprising administering intravenously to said patient a pharmaceutical composition comprising cytarabine and daunorubicin at a fixed, molar ratio of cytarabine to daunorubicin of about 5:1 in an administration step of 8 hours or less,
wherein said fixed ratio is maintained in the plasma for at least 4 hours, and
wherein said fixed, molar ratio of cytarabine and daunorubicin is encapsulated in liposomes;
wherein the composition is administered to provide cytarabine in an amount of 32-134 mg/m 2 and a total amount of 96-402 mg/m 2 in a cycle of administration consisting of a first administration step on day 1, a second administration step on day 3, and a third administration step on day 5; and
wherein the liposomes comprise DSPC:DSPG:cholesterol at 7:2:1 molar ratio.
2. The method of claim 1 wherein the composition is administered in 3 hours or less for each administration step.
3. The method of claim 2 , wherein the composition is administered in 90 minutes or less for each administration step.
4. The method of claim 1 , wherein said administration is by intravenous (IV) drip.
5. The method of claim 1 , wherein the leukemia is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML) or acute promyelocytic leukemia (APL).
6. The method of claim 1 , wherein said subject has previously undergone at least one anti-cancer regimen, and/or has previously experienced a remission.
7. The method of claim 6 wherein said subject has experienced a relapse within 18 months after said anticancer regimen.
8. The method of claim 7 wherein said subject has experienced a relapse within 6 months after said anticancer regimen.
9. The method of claim 1 , which further includes measuring a therapeutic effect as a function of increase in complete remission rate, and/or as a function of prolongation of complete remission duration and/or prolongation of time to progression and/or prolongation of survival.
10. The method of claim 1 , which further includes measuring an improved safety result as a reduction in non-hematopoietic toxicities.
11. The method of claim 10 , wherein the non-hematopoietic toxicities are mucositis and/or alopecia.